Skin Cancer & Melanoma

Latest News

Phase 2 data also show responses with atezolizumab switch therapy in a population of patients with BRAF V600–positive melanoma.
Survival Improves With Atezolizumab Switch Therapy in BRAF+ Melanoma

September 17th 2024

Phase 2 data also show responses with atezolizumab switch therapy in a population of patients with BRAF V600–positive melanoma.

Support for the decision follows phase 1 findings evaluating IBI363 in patients with advanced solid tumors presented at the 2024 ESMO Plenary.
IBI363 Monotherapy Gets Fast Track Status for Advanced Melanoma

September 5th 2024

Preliminary results from part 2 of the phase 2 trial evaluating VP-315 in basal cell carcinoma found no dose-limiting toxicities or treatment-related serious adverse events.
Encouraging Tumor Shrinkage Observed in VP-315 for Basal Cell Carcinoma

August 28th 2024

The Melanoma Research Alliance mourns the passing of Jeffrey S. Weber, MD, PhD, a pioneer in developing immunotherapy for patients with melanoma.
Melanoma Research Pioneer Jeffrey S. Weber, MD, PhD, Dies

August 19th 2024

Data from the phase 3 MELATORCH study support the supplemental new drug application for frontline toripalimab in unresectable or metastatic melanoma.
China’s NMPA Accepts sNDA for Frontline Toripalimab in Metastatic Melanoma

August 13th 2024

Latest CME Events & Activities

Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board

View More

Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!

View More

Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer

View More

Tumor-Infiltrating Lymphocyte Therapy Advances Into Melanoma

View More

Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care

View More

<1
...
2425262728